小野薬品、再発の多発性骨髄腫患者を対象とした第III相試験においてKyprolis®（カルフィルゾミブ）の併用療法が有意に全生存期間の延長を示す  ( Second Phase III Study Shows Kyprolis® (Carfilzomib) Regimen Significantly Improves Overall Survival in Patients with Relapsed Multiple Myeloma ）

By Pharmaceutical

再発の多発性骨髄腫患者を対象とした第III相試験においてKyprolis®（カルフィルゾミブ）の併用療法が有意に全生存期間の延長を示す ニュースリリース｜小野薬品工業株式会社 

http://www.ono.co.jp/jpnw/PDF/n17_0713.pdf

Jul.13.2017……Second Phase III Study Shows Kyprolis® (Carfilzomib) Regimen Significantly Improves Overall Survival in Patients with Relapsed Multiple Myeloma

https://www.ono.co.jp/eng/news/pdf/sm_cn170713.pdf

More from tokioX :

  1. FDA ：Opdivo® as the First New Medication for Certain Patients with Previously Treated Small Cell Lung Cancer
  2. 💊Karyopharm’s Selinexor Receives Fast Track Designation from FDA for the Treatment of Patients with Penta-Refractory Multiple Myeloma
  3. 💊Sunovion Announces Positive Topline Results from Pivotal Study of Apomorphine Sublingual Film (APL-130277) in Patients with Parkinson’s Disease
  4. 💊Opdivo Plus Yervoy Combination Delivered Overall Survival Benefit Across PD-L1 Expression Levels in Intermediate- and Poor-Risk Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
  5. ono、Opdivo Plus Yervoy Combination Demonstrated Superior Overall Survival and Showed Durable Responses in Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
  6. Long-Term Analysis of Phase 3 Head-To-Head Study Confirms KYPROLIS® (Carfilzomib) Regimen Extends Overall Survival in Patients with Relapsed Multiple Myeloma News Release 20170901
  7. オプジーボ®（一般名:ニボルマブ）の安全性と有効性を評価した第Iii相臨床試験において主要評価項目が達成される  ( Phase 3 Study Evaluating the Safety and Efficacy of Adjuvant Opdivo in Resected High-Risk Melanoma Patients Meets Primary Endpoint )  Opdivo    Phase 3